Drug intelligence / Profile preview

ScTIL

Development stage: Phase 2
Lead developer: Peking University Cancer Hospital & Institute
Modality: Cell Therapies
Administration: Intravenous

Overview

ScTIL is a cell therapy that utilizes genetically modified tumor-infiltrating lymphocytes (TILs). It is being investigated for its safety, pharmacokinetic characteristics, and efficacy in the treatment of various recurrent or refractory gynecological malignancies, advanced malignant solid tumors, melanoma, and digestive system malignant solid tumors. The therapy aims to induce an anti-tumor immune response.

Other names: Genetically Modified Tumor Infiltrating LymphocytesSuper circulating tumor infiltrating lymphocytes

Beyond the preview

Go deeper on ScTIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ScTIL.

Explore the full profile